Emerging Company Profiles

Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.   

Emerging Company Profile: Scotland-based EnteroBiotix will use proceeds from a successful series A financing to advance its nascent pipeline of novel high-diversity microbial therapeutics, enhancing the gut microbiome and eventually targeting multiple indications.

Emerging Company Profile: Armed with fresh funds, French spin-out PEP-Therapy will begin a clinical proof of concept study assessing its lead therapeutic peptide as a potential treatment for metastatic triple-negative breast cancer and platinum-resistant ovarian cancer.

Emerging Company Profile: Backed by investors including Novo Holdings, HealthCap and RA Capital Management, Hemab Therapeutics is bringing together strong technology and deep expertise to ‘leapfrog’ treatment for several rare bleeding and thrombosis disorders into the 21st century.

Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.

Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.

Emerging Company Profile: While vaccines target specific viruses, Dutch start-up Leyden Labs is hunting down commonalities in viral families and working on the delivery of intranasal molecules that can protect humans from both known and future viruses.

Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.

Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.

Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.

Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023.

Emerging Company Profile: Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.